You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Teleflex raised 2026 adjusted EPS guidance to $7.50 to $7.75 from $6.90 to $7.20, citing third-quarter performance. Revenue was $567.8 million, adjusted EPS was $2.63, and pro forma adjusted constant currency revenue grew 3.0%.
Teleflex reported third-quarter revenue of $567.8 million, up 0.2%, and raised 2026 adjusted diluted EPS guidance to $7.50 to $7.75. The OEM divestiture yielded $1.5 billion in cash; the Acute Care and Interventional Urology sale to Intersurgical Ltd. is pending.
Useful current figures from the complete screener profile.
TL;DR. Teleflex reported 39.2% adjusted EPS growth and 300-basis-point adjusted operating-margin expansion, raised 2026 adjusted EPS and operating-margin guidance, and accelerated share repurchases and debt reduction. Vascular and Surgical remained strong while Interventional returned to modest growth. Risks included lower GAAP revenue guidance, Interventional integration disruption, possible divestiture delay into 2027, Q4 margin contraction, weaker nine-month adjusted margins, and continued tariff costs.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted diluted earnings per share from continuing operations non-GAAP | $3.14 | Six Months Ended June 30, 2026 | — |
| Adjusted effective tax rate non-GAAP | 13.8% | Six Months Ended June 30, 2026 | — |
| Adjusted gross margin non-GAAP | 61.5% | Six Months Ended June 30, 2026 | — |
| Adjusted operating margin non-GAAP | 18.8% | Six Months Ended June 30, 2026 | — |
| Pro forma adjusted revenue non-GAAP | $1.12B | Six Months Ended June 30, 2026 | — |
| Pro Forma adjusted revenue growth (constant currency) non-GAAP | 4.9% | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TFX
this stock
Teleflex Inc
|
$6.15B | +27.1% | +17.2% | 18.9 | 10.3% |
|
ISRG
Intuitive Surgical Inc
|
$153.77B | -21.7% | +20.5% | 53.8 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$59.39B | — | +8.2% | 96.5 | 3.0% |
|
MDLN
Medline Inc.
|
$51.92B | -6.0% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.61B | -6.0% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Teleflex reported third-quarter revenue of $567.8 million, up 0.2%, and raised 2026 adjusted diluted EPS guidance to $7.50 to $7.75. The OEM divestiture yielded $1.5 billion in cash; the Acute Care and Interventional Urology sale to Intersurgical Ltd. is pending.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TFX | +2.8% | +18.9% | +17.6% | +11.0% | +27.1% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +0.2% | +20.1% | +17.1% | +11.2% | +16.5% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
